Drug intelligence / Profile preview

aspirin + clopidogrel + celecoxib

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of two antiplatelet agents (aspirin and clopidogrel) and a selective COX-2 inhibitor (celecoxib). This combination is used in patients who require both antiplatelet therapy for cardiovascular conditions and anti-inflammatory treatment for conditions such as arthritis. Studies have shown that celecoxib does not interfere with the antiplatelet effects of aspirin and clopidogrel, making it a safer option compared to other NSAIDs when dual antiplatelet therapy is required.

Targets

P2Y12 (Purinergic P2Y12 receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on aspirin + clopidogrel + celecoxib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aspirin + clopidogrel + celecoxib.

Explore the full profile